Virtus Biotech Clinical Trials ETF
17 hedge funds and large institutions have $2.11M invested in Virtus Biotech Clinical Trials ETF in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.
6% less funds holding
Funds holding: 18 → 17 (-1)
9.69% less ownership
Funds ownership: 27.79% → 18.11% (-9.7%)
31% less capital invested
Capital invested by funds: $3.06M → $2.11M (-$949K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$605K |
| 2 |
Comerica Bank
Dallas,
Texas
|
+$7.76K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$329 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$973K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$913K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$20.6K |
| 4 |
DI
DAGCO Inc
Westlake,
Ohio
|
-$19.6K |
| 5 |
LPL Financial
San Diego,
California
|
-$5.51K |
BBC Hedge Fund Activity: Q1 2024 in Review
17 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2024, worth a combined $2.11M — down 31% from $3.06M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBC and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $605K. The largest seller was Susquehanna International Group, cutting an estimated $973K.
- 17 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2024, down from 18 in Q4 2023.
- Funds reported $2.11M of Virtus Biotech Clinical Trials ETF stock for Q1 2024, down 31% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2024 was Morgan Stanley, an estimated $605K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2024 was Susquehanna International Group, an estimated $973K sold.
Based on aggregated 13F filings for Q1 2024.